ArticleInternational journal of clinical and experimental pathology2015
Effects of interleukin-37 on cardiac function after myocardial infarction in mice.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Inflammaging and cytokine-driven cardiovascular senescence in age-related myocardial infarction: mechanisms, biomarkers, and precision immunotherapy strategies.Biogerontology · 2026Review
- NF-Frontiers in cardiovascular medicine · 2026Review
- The Protective Role of Interleukin-37 in Cardiovascular Diseases through Ferroptosis Modulation.International journal of molecular sciences · 2024Review
- Association of theDiagnostics (Basel, Switzerland) · 2021Article
- Role of IL-37- and IL-37-Treated Dendritic Cells in Acute Coronary Syndrome.Oxidative medicine and cellular longevity · 2021Review
- Interleukin-37 contributes to the pathogenesis of gout by affecting PDZ domain-containing 1 protein through the nuclear factor-kappa B pathway.The Journal of international medical research · 2020Article
- Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.Circulation research · 2020Review
- Potential role of IL-37 in atherosclerosis.Cytokine · 2019Review
- IL-37 increases in patients after ischemic stroke and protects from inflammatory brain injury, motor impairment and lung infection in mice.Scientific reports · 2019Article
- Interleukin-37: The Effect of Anti-Inflammatory Response in Human Coronary Artery Endothelial Cells.Mediators of inflammation · 2019Review
- The Role, Involvement and Function(s) of Interleukin-35 and Interleukin-37 in Disease Pathogenesis.International journal of molecular sciences · 2018Review
- Interleukin-37: A crucial cytokine with multiple roles in disease and potentially clinical therapy.Oncology letters · 2018Article
- Reviews of Interleukin-37: Functions, Receptors, and Roles in Diseases.BioMed research international · 2018Review
- Measurement of Elevated IL-37 Levels in Acute Ischemic Brain Injury: A Cross-sectional Pilot Study.Cureus · 2017Article
- The emerging role of interleukin-37 in cardiovascular diseases.Immunity, inflammation and disease · 2017Review
- Interleukin-37 elevation in patients with atrial fibrillation.Clinical cardiology · 2017Article
- Plasma IL-37 Elevated in Patients with Chronic Heart Failure and Predicted Major Adverse Cardiac Events: A 1-Year Follow-Up Study.Disease markers · 2017Article
- FGF-16 protects against adverse cardiac remodeling in the infarct diabetic heart.American journal of translational research · 2017Article
- Interleukin-37 and Dendritic Cells Treated With Interleukin-37 Plus Troponin I Ameliorate Cardiac Remodeling After Myocardial Infarction.Journal of the American Heart Association · 2016Article
- Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout.Arthritis research & therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterleukin-37 (IL-37) is a new discovered member of the interleukin family and plays anti-inflammatory effect in some inflammatory disease. A recent study found that IL-37 elevated significantly in peripheral blood of patients with acute myocardial infarction. We aimed to explore the effect IL-37 on cardiac function after mice myocardial infarction (MI) and its mechanism.
methodsAcute MI mouse model was established and divided into three groups: sham group, MI group and IL-37 treatment group. MPO expression was detected by immunohistochemistry; NF-κB signaling pathway was tested by Western blot; and cardiac function was measured by echocardiography.
resultsCompared with MI mice, IL-37 treatment showed an obvious decrease of MPO expression, suppression of p-p65 expression, and improved cardiac function by decreasing left ventricular shortening fraction (LVFS).
conclusionIL-37 may improve MI mice cardiac function via inhibition of inflammatory NF-κB signaling pathway.
Indexed as
Identifiers
26191225PMC4503097W943902575What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.